Wordt geladen...
Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer
PURPOSE: HR+/HER2− aromatase inhibitor (AI)-resistant metastatic breast cancer can be treated with everolimus and a second AI until the cancer recurs. Targeting these everolimus-resistant patients with the latest standard of care, CDK4/6 inhibitors, has not been clearly addressed. Understanding the...
Bewaard in:
| Gepubliceerd in: | Breast Cancer Res Treat |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026053/ https://ncbi.nlm.nih.gov/pubmed/29623577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4779-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|